These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

523 related items for PubMed ID: 24612982

  • 1. Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration.
    Varghese JM, Jarrett P, Boots RJ, Kirkpatrick CM, Lipman J, Roberts JA.
    Int J Antimicrob Agents; 2014 Apr; 43(4):343-8. PubMed ID: 24612982
    [Abstract] [Full Text] [Related]

  • 2. Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.
    Roger C, Cotta MO, Muller L, Wallis SC, Lipman J, Lefrant JY, Roberts JA.
    Int J Antimicrob Agents; 2017 Aug; 50(2):227-231. PubMed ID: 28689876
    [Abstract] [Full Text] [Related]

  • 3. Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?
    Varghese JM, Jarrett P, Wallis SC, Boots RJ, Kirkpatrick CM, Lipman J, Roberts JA.
    J Antimicrob Chemother; 2015 Feb; 70(2):528-33. PubMed ID: 25336163
    [Abstract] [Full Text] [Related]

  • 4. Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure.
    Valtonen M, Tiula E, Takkunen O, Backman JT, Neuvonen PJ.
    J Antimicrob Chemother; 2001 Dec; 48(6):881-5. PubMed ID: 11733473
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
    Awissi DK, Beauchamp A, Hébert E, Lavigne V, Munoz DL, Lebrun G, Savoie M, Fagnan M, Amyot J, Tétreault N, Robitaille R, Varin F, Lavallée C, Pichette V, Leblanc M.
    Pharmacotherapy; 2015 Jun; 35(6):600-7. PubMed ID: 26095008
    [Abstract] [Full Text] [Related]

  • 6. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
    Roberts DM, Roberts JA, Roberts MS, Liu X, Nair P, Cole L, Lipman J, Bellomo R, RENAL Replacement Therapy Study Investigators.
    Crit Care Med; 2012 May; 40(5):1523-8. PubMed ID: 22511133
    [Abstract] [Full Text] [Related]

  • 7. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
    Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J.
    Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
    [Abstract] [Full Text] [Related]

  • 8. Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements.
    Ulldemolins M, Martín-Loeches I, Llauradó-Serra M, Fernández J, Vaquer S, Rodríguez A, Pontes C, Calvo G, Torres A, Soy D.
    J Antimicrob Chemother; 2016 Jun; 71(6):1651-9. PubMed ID: 26869692
    [Abstract] [Full Text] [Related]

  • 9. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J, Min KL, Kang S, Yang S, Park MS, Wi J, Chang MJ.
    Microbiol Spectr; 2021 Dec 22; 9(3):e0063321. PubMed ID: 34937189
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
    Sturm AW, Allen N, Rafferty KD, Fish DN, Toschlog E, Newell M, Waibel B.
    Pharmacotherapy; 2014 Jan 22; 34(1):28-35. PubMed ID: 23864417
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT.
    Shotwell MS, Nesbitt R, Madonia PN, Gould ER, Connor MJ, Salem C, Aduroja OA, Amde M, Groszek JJ, Wei P, Taylor ME, Tolwani AJ, Fissell WH.
    Clin J Am Soc Nephrol; 2016 Aug 08; 11(8):1377-1383. PubMed ID: 27197907
    [Abstract] [Full Text] [Related]

  • 12. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
    Asín-Prieto E, Rodríguez-Gascón A, Trocóniz IF, Soraluce A, Maynar J, Sánchez-Izquierdo JÁ, Isla A.
    J Antimicrob Chemother; 2014 Jan 08; 69(1):180-9. PubMed ID: 23908259
    [Abstract] [Full Text] [Related]

  • 13. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.
    Roberts JA, Udy AA, Bulitta JB, Stuart J, Jarrett P, Starr T, Lassig-Smith M, Roberts NA, Dunlop R, Hayashi Y, Wallis SC, Lipman J.
    J Antimicrob Chemother; 2014 Sep 08; 69(9):2508-16. PubMed ID: 24879665
    [Abstract] [Full Text] [Related]

  • 14. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
    Cies JJ, Shankar V, Schlichting C, Kuti JL.
    Pediatr Infect Dis J; 2014 Feb 08; 33(2):168-73. PubMed ID: 23907263
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration.
    Jamal JA, Roberts DM, Udy AA, Mat-Nor MB, Mohamad-Nor FS, Wallis SC, Lipman J, Roberts JA.
    Int J Antimicrob Agents; 2015 Jul 08; 46(1):39-44. PubMed ID: 25881872
    [Abstract] [Full Text] [Related]

  • 16. Variability of piperacillin concentrations in relation to tazobactam concentrations in critically ill patients.
    Zander J, Döbbeler G, Nagel D, Scharf C, Huseyn-Zada M, Jung J, Frey L, Vogeser M, Zoller M.
    Int J Antimicrob Agents; 2016 Oct 08; 48(4):435-9. PubMed ID: 27476810
    [Abstract] [Full Text] [Related]

  • 17. A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam.
    Martínková J, Malbrain ML, Havel E, Šafránek P, Bezouška J, Kaška M.
    Anaesthesiol Intensive Ther; 2016 Oct 08; 48(1):23-8. PubMed ID: 26588478
    [Abstract] [Full Text] [Related]

  • 18. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients.
    Dhaese SAM, Roberts JA, Carlier M, Verstraete AG, Stove V, De Waele JJ.
    Int J Antimicrob Agents; 2018 Apr 08; 51(4):594-600. PubMed ID: 29277531
    [Abstract] [Full Text] [Related]

  • 19. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
    Nichols K, Chung EK, Knoderer CA, Buenger LE, Healy DP, Dees J, Crumby AS, Kays MB.
    Antimicrob Agents Chemother; 2016 Jan 08; 60(1):522-31. PubMed ID: 26552978
    [Abstract] [Full Text] [Related]

  • 20. Concentrations of piperacillin-tazobactam in human jaw and hip bone.
    Al-Nawas B, Kinzig-Schippers M, Soergel F, Shah PM.
    J Craniomaxillofac Surg; 2008 Dec 08; 36(8):468-72. PubMed ID: 18783957
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.